ClinicalTrials.gg
CompletedNCT05891483Updated Jul 22, 2026

Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

A Phase 2 interventional study of SHR-1905 Injection and SHR-1905 Placebo Injection in Chronic Rhinosinusitis With Nasal Polyps, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.

Enrollment
16th of 43
114 · median 90
Started
2023
with 5 others
Phase 2
13 of 46
4 open now
Registered
22nd of 46
by date
Lead sponsor
2 of 46
Guangdong Hengrui Pharmaceutical Co., Ltd

Among the 46 studies in Nasal Polyps with a site in China, this one is the 16th largest by enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2023, is one of 13 in phase 2, and was the 22nd registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Nasal Polyps with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy, and safety of SHR-1905 injection in subjects with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to explore the reasonable dosage of SHR-1905 injection for CRSwNP.

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Weight ≥40kg
  2. Diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP).
  3. Bilateral nasal polyps at screening and baseline, total NPS ≥5, ≥2 points for each nostril.
  4. NCS ≥2 at screening and baseline.
  5. SNOT-22≥20 at screening period and baseline.
  6. Recorded persistent NP symptoms for over 4 weeks prior to screening.
  7. Subjects received standard therapy with intranasal (INCS) and remained stable during the 4 weeks prior to randomization.
  8. NP surgery in the past and/or ACERS treated with SCS occurred within 2 years before randomization (or with / intolerances).

Exclusion criteria

Exclusion Criteria:

  1. Any comorbidities that may affect the efficacy evaluation of nasal polyps.
  2. Any comorbidities except for asthma that may affect blood EOS levels.
  3. Concomitant with immunodeficiency.
  4. Concomitant with or not suitable for nasal endoscopy.
  5. Uncontrolled hypertension.
  6. Uncontrolled diabetes.
  7. Infection within 2 weeks prior to screening to randomization that is and/or should be treated with systemic antibiotics.
  8. Uncontrolled epistaxis within 4 weeks prior to randomization.
  9. Major surgery performed within 3 months prior to randomization, or surgery planned during the study, or treatments that may affect evaluations according to investigators.
  10. Parasitic infection within 6 months before randomization.
  11. Sinus or intranasal surgery (except for diagnostic ) within 6 months prior to randomization, or changes in the nasal walls caused by sinus or intranasal surgery that made NPS evaluation impossible.
  12. diagnosed within 5 years before randomization (except those with a low risk of or death).
  13. Abnormalities of laboratory tests at screening or baseline.
  14. Concomitant with active , positive virus antibodies, positive antibodies, or positive treponema pallidum antibodies.
  15. Prolonged (>450ms for male and >470ms for female) or other clinically significant abnormal results of at screening or baseline that may cause significant safety risks to subjects.
  16. before the use of bronchodilator (pre-BD) was less than 50% at screening.
  17. Transfusion of blood products or immunoglobulin within 4 weeks prior to randomization.
  18. SCS or additional INCS use within 4 weeks before randomization, or planned use during treatment period.
  19. Regular use of decongestants (local or systemic) within 4 weeks before randomization, except for during the endoscopic procedure.
  20. Adnimistration of or viral vector vaccine within 4 weeks before randomization.
  21. Allergen immunotherapy within 8 weeks before randomization.
  22. Smoking history ≥10 pack-years, smoking at screening, or smoking cessation less than 6 months at screening.
  23. Substance abuse, drug abuse, and/or excessive alcohol consumption within 1 year prior to randomization.
  24. Pregnancy (including positive pregnancy test at screening or baseline), lactation, or pregnancy plan during study period.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Treatment group A: SHR-1905 Injection(dose 1)

    Drug: SHR-1905 Injection

  • Experimental
    Treatment group B: SHR-1905 Injection(dose 2)

    Drug: SHR-1905 Injection

  • Experimental
    Treatment group C: SHR-1905 Injection(dose 3)

    Drug: SHR-1905 Injection

  • Placebo comparator
    Placebo Group

    Drug: SHR-1905 Placebo Injection

Interventions

  • SHR-1905 Injection

  • DrugSHR-1905 Placebo Injection

    SHR-1905 Placebo Injection

06

What researchers measure

Primary outcomes

  1. Nasal polyp scores (NPS)

    Change from baseline in NPS at Week 24.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. NPS

    Changes from baseline in NPS from baseline at each evaluation time point.

    Time frame: Baseline to Week 48

  2. Nasal Congestion Scores (NCS)

    Changes from baseline in NCS at each evaluation time point.

    Time frame: Baseline to Week 48

  3. Loss of smell

    Changes from baseline in scores of loss of smell at each evaluation time point.

    Time frame: Baseline to Week 48

  4. Runny nose/postnasal drip

    Change from baseline in scores of runny nose/postnasal drip at each evaluation time point.

    Time frame: Baseline to Week 48

  5. Facial pain and/or pressure

    Change from baseline in facial pain and/or pressure scores at each evaluation time point.

    Time frame: Baseline to Week 48

  6. Total symptoms score (TSS)

    Changes from baseline in TSS each evaluation time point.

    Time frame: Baseline to Week 48

  7. Sino-nasal outcome test-22 (SNOT-22) scores

    Changes from baseline in SNOT-22 scores at each evaluation time point.

    Time frame: Baseline to Week 48

  8. Proportion of subjects exposed to SCS for acute exacerbation of chronic rhinosinusitis (AECRS) over 24 weeks.

    Time frame: Baseline to Week 24

  9. Dose of SCS used for AECRS over 24 weeks (converted to equivalent dose of prednisone).

    Time frame: Baseline to Week 24

07

Study locations

1 site
  • Eye & Ent Hospital of Fudan University
    Shanghai, Shanghai Municipality 200031, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Jan 2026, 28 months.

Of 24 phase 2 interventional studies under Nasal Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 32. This study's 28 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Jun 7, 2023
StartActual
Sep 4, 2023
Primary completionActual
Jan 21, 2026
CompletionActual
Jan 21, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05891483
Responsible party
Sponsor
First posted
Jun 7, 2023
Start date
Sep 4, 2023
Primary completion
Jan 21, 2026
Completion
Jan 21, 2026
Last update
Jul 22, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1905

Start the discussion